News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
MedWatch: Update of Safety Review of Montelukast (Singulair)
January 27, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
On March 27, 2008, FDA announced that it was reviewing safety data that raised concerns about a possible association between the use of montelukast and behavior/mood changes, suicidality (suicidal thinking and behavior) and suicide.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
CDC
CDC Adopts ACIP Recommendations on Chickenpox, COVID-19 Vaccines
October 6, 2025
·
1 min read
·
Heather McKenzie
Regulatory
Fired NIAID Director Claims Ouster Was Payback for Whistleblower Report
October 3, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
CMS Finalizes Stronger Protections for Orphan Drugs Against IRA Price Negotiations
October 3, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Delays Pharma Tariffs Yet Again
October 2, 2025
·
2 min read
·
Tristan Manalac
